Antitubulin agents for the treatment of cancer - A medicinal chemistry update

Neeraj Mahindroo, Jing Ping Liou, Jang Yang Chang, Hsing Pang Hsieh

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.

Original languageEnglish
Pages (from-to)647-691
Number of pages45
JournalExpert Opinion on Therapeutic Patents
Volume16
Issue number5
DOIs
Publication statusPublished - May 2006

Fingerprint

Pharmaceutical Chemistry
Microtubules
patent
cancer
chemistry
drug
Vinca Alkaloids
Taxoids
Kinesin
Neoplasms
Patents
Medical Oncology
Excipients
Multiple Drug Resistance
Cell Division
Therapeutics
Research
literature
Proteins

Keywords

  • Antitubulin
  • Kinesin-like spindle protein inhibitor
  • Medicinal chemistry
  • Microtubule-destabilising agent
  • Microtubule-stabilising agent

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law

Cite this

Antitubulin agents for the treatment of cancer - A medicinal chemistry update. / Mahindroo, Neeraj; Liou, Jing Ping; Chang, Jang Yang; Hsieh, Hsing Pang.

In: Expert Opinion on Therapeutic Patents, Vol. 16, No. 5, 05.2006, p. 647-691.

Research output: Contribution to journalArticle

Mahindroo, Neeraj ; Liou, Jing Ping ; Chang, Jang Yang ; Hsieh, Hsing Pang. / Antitubulin agents for the treatment of cancer - A medicinal chemistry update. In: Expert Opinion on Therapeutic Patents. 2006 ; Vol. 16, No. 5. pp. 647-691.
@article{5806eec66b2a4236bad2d1d03c59cdb4,
title = "Antitubulin agents for the treatment of cancer - A medicinal chemistry update",
abstract = "The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.",
keywords = "Antitubulin, Kinesin-like spindle protein inhibitor, Medicinal chemistry, Microtubule-destabilising agent, Microtubule-stabilising agent",
author = "Neeraj Mahindroo and Liou, {Jing Ping} and Chang, {Jang Yang} and Hsieh, {Hsing Pang}",
year = "2006",
month = "5",
doi = "10.1517/13543776.16.5.647",
language = "English",
volume = "16",
pages = "647--691",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Antitubulin agents for the treatment of cancer - A medicinal chemistry update

AU - Mahindroo, Neeraj

AU - Liou, Jing Ping

AU - Chang, Jang Yang

AU - Hsieh, Hsing Pang

PY - 2006/5

Y1 - 2006/5

N2 - The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.

AB - The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.

KW - Antitubulin

KW - Kinesin-like spindle protein inhibitor

KW - Medicinal chemistry

KW - Microtubule-destabilising agent

KW - Microtubule-stabilising agent

UR - http://www.scopus.com/inward/record.url?scp=33646551448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646551448&partnerID=8YFLogxK

U2 - 10.1517/13543776.16.5.647

DO - 10.1517/13543776.16.5.647

M3 - Article

VL - 16

SP - 647

EP - 691

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 5

ER -